Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Turner

Interventional Cardiology Birmingham, AL Medical Doctor

NPI 1225355514 CMS profile 2788855

100 Pilot Medical Dr, Suite 300, Birmingham, AL 35235

Open in the dashboard

General payments

$4,962

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Turner of Birmingham, AL is reported in the CMS Open Payments database as having received $4,962 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $791 47
2024 General $629 39
2023 General $658 42
2022 General $749 39
2021 General $193 10
2020 General $1,254 25
2019 General $687 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Turner
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Joshua Turner were reported at $791. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Joshua Turner Interventional Cardiology median Middle half National median
2019 $687 $1,097 $329–$3,048 $163
2020 $1,254 $473 $161–$1,480 $114
2021 $193 $677 $233–$1,827 $132
2022 $749 $978 $333–$2,724 $149
2023 $658 $1,136 $382–$2,986 $160
2024 $629 $1,181 $395–$3,326 $164
2025 $791 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,358 87 payments
  2. Edwards Lifesciences Corporation $995 9 payments
  3. Pfizer Inc. $524 33 payments
  4. Janssen Pharmaceuticals, Inc $263 16 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $245 15 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $231 14 payments
  7. Abbott Laboratories $201 3 payments
  8. Amgen Inc. $200 14 payments
  9. E.R. Squibb & Sons, L.L.C. $136 7 payments
  10. Organogenesis Inc. $118 1 payment
  11. Other $692 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,227 236 payments
  2. Travel and Lodging $734 2 payments
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Transcatheter Heart Valve $977 8 payments
  2. LEQVIO $652 41 payments
  3. ENTRESTO Cardiovascular $541 33 payments
  4. ELIQUIS $325 22 payments
  5. VYNDAQEL $289 17 payments
  6. XARELTO $263 16 payments
  7. LifeVest $245 15 payments
  8. ENTRESTO Cardiology/Vascular Diseases $180 12 payments
  9. Repatha $168 12 payments
  10. Mitra Clip system $143 1 payment
  11. Other $1,788 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

4,057

Median for Interventional Cardiology: 2,236

Drug cost

$753,045

Median for Interventional Cardiology: $380,412

Branded share of claims

31.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 599 $538,673
Repatha Sureclick Evolocumab Brand 106 $63,057
Xarelto Rivaroxaban Brand 33 $33,110
Jardiance Empagliflozin Brand 17 $22,229
Entresto Sacubitril/Valsartan Brand 13 $13,778
Praluent Pen Alirocumab Brand 18 $8,724
Brilinta Ticagrelor Brand 14 $7,707
Atorvastatin Calcium Generic 432 $6,943
Fenofibrate Generic 16 $6,468
Exforge Hct Amlodipine/Valsartan/Hcthiazid Brand 12 $5,300

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$329,145

Of which drugs: $1,870

Medicare patients

700

Average age 76

Services billed

2,901

350 women, 350 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 47%
Diabetes 45%
Chronic kidney disease 41%
Atrial fibrillation 39%
Heart failure 35%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 87 336 $1,853

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $109
$109 — —
ELIQUIS
  • PFIZER INC. $62
  • E.R. Squibb & Sons, L.L.C. $20
$82 599 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
$67 17 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $49
$49 13 —
XARELTO
  • Janssen Pharmaceuticals, Inc $33
$33 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record